International immunopharmacology · 2026
c-MET/NF-κB axis modulates PD-L1 and CCL22-mediated immune evasion and its inhibition enhances anti-PD-1 efficacy in non-small cell lung cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Lijin, Yao Xihu, Su Chunyang, Zheng Jinyang, Fan Rencai, Zhang Liping, Chen Hao, Li Xiaofeng, Lin Xiaoyan
Аннотация
BACKGROUND: c-MET overexpression is common in non-small cell lung cancer (NSCLC) and associated with poor prognosis, however, its role in immune evasion and immunotherapy resistance remains unclear.
METHODS: We analyzed c-MET expression in public "The Cancer Genome Atlas NSCLC" cohort (n = 1043) and an institutional cohort of 117 NSCLC patients, including 57 advanced cases receiving first-line immunochemotherapy. c-MET expression was assessed via immunohistochemistry and correlated with clinical outcomes and immune markers. Mechanistic studies used c-MET knockdown/overexpression in H1993 and LLC cells, combined with RNA-seq, western blotting, immunofluorescence, and flow cytometry. The in vivo efficacy of capmatinib plus anti-PD-1 antibodies was evaluated using a syngeneic mouse model.
RESULTS: c-MET overexpression was associated with shorter overall and progression-free survival in patients receiving immunochemotherapy and emerged as a potential prognostic factor in this exploratory cohort. c-MET-high tumors exhibited increased PD-L1 expression, reduced CD8+ T cell infiltration, and enrichment of immunosuppressive populations. Mechanistically, c-MET engaged the NF-κB pathway, consistent with coordinated upregulation of PD-L1 and CCL22, as supported by both NF-κB inhibition and agonist rescue. In vivo, c-MET overexpression promoted tumor growth and altered tumor immune cell composition. Combined MET inhibition (capmatinib) and PD-1 blockade synergistically suppressed tumor growth, increased CD8+ T and NK cell infiltration, and reduced regulatory T cells, M2 macrophages, and myeloid-derived suppressor cells; no overt toxicity was noted.
CONCLUSION: c-MET overexpression promotes immune evasion in NSCLC, potentially through NF-κB-mediated upregulation of PD-L1 and CCL22. Combined MET inhibition and immune checkpoint blockade represents a promising strategy for this patient subset.
METHODS: We analyzed c-MET expression in public "The Cancer Genome Atlas NSCLC" cohort (n = 1043) and an institutional cohort of 117 NSCLC patients, including 57 advanced cases receiving first-line immunochemotherapy. c-MET expression was assessed via immunohistochemistry and correlated with clinical outcomes and immune markers. Mechanistic studies used c-MET knockdown/overexpression in H1993 and LLC cells, combined with RNA-seq, western blotting, immunofluorescence, and flow cytometry. The in vivo efficacy of capmatinib plus anti-PD-1 antibodies was evaluated using a syngeneic mouse model.
RESULTS: c-MET overexpression was associated with shorter overall and progression-free survival in patients receiving immunochemotherapy and emerged as a potential prognostic factor in this exploratory cohort. c-MET-high tumors exhibited increased PD-L1 expression, reduced CD8+ T cell infiltration, and enrichment of immunosuppressive populations. Mechanistically, c-MET engaged the NF-κB pathway, consistent with coordinated upregulation of PD-L1 and CCL22, as supported by both NF-κB inhibition and agonist rescue. In vivo, c-MET overexpression promoted tumor growth and altered tumor immune cell composition. Combined MET inhibition (capmatinib) and PD-1 blockade synergistically suppressed tumor growth, increased CD8+ T and NK cell infiltration, and reduced regulatory T cells, M2 macrophages, and myeloid-derived suppressor cells; no overt toxicity was noted.
CONCLUSION: c-MET overexpression promotes immune evasion in NSCLC, potentially through NF-κB-mediated upregulation of PD-L1 and CCL22. Combined MET inhibition and immune checkpoint blockade represents a promising strategy for this patient subset.